ArticleEuropean radiology2021
Liver MRI with amide proton transfer imaging: feasibility and accuracy for the characterization of focal liver lesions.
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Single-breath-hold 3D abdominal metabolic MRI enables label-free diagnosis of liver cancer.Nature communications · 2026Article
- Human liver CEST imaging at 7 T: Impact ofMagnetic resonance in medicine · 2025Article
- Feasibility of Sodium and Amide Proton Transfer-Weighted Magnetic Resonance Imaging Methods in Mild Steatotic Liver Disease.Tomography (Ann Arbor, Mich.) · 2025Article
- Image quality assessment and feasibility of three-dimensional amide proton transfer-weighted imaging for hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2024Article
- An update on liver chemical exchange saturation transfer imaging with a focus on clinical translation.Quantitative imaging in medicine and surgery · 2023Article
- CEST-MRI for body oncologic imaging: are we there yet?NMR in biomedicine · 2023Review
- Free-breathing 3D CEST MRI of human liver at 3.0 T.Magnetic resonance in medicine · 2023Article
- Amide proton transfer weighted (APTw) imaging based radiomics allows for the differentiation of gliomas from metastases.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the feasibility of using amide proton transfer (APT) magnetic resonance imaging (MRI) in the liver and to evaluate its ability to characterize focal liver lesions (FLLs).
methodsA total of 203 patients with suspected FLLs who underwent APT imaging at 3T were included. APT imaging was obtained using a single-slice turbo spin-echo sequence to include FLLs through five breath-holds, and its acquisition time was approximately 1 min. APT signals in the background liver and FLL were measured with magnetization transfer ratio asymmetry (MTR
resultsThe technical success rate of APT imaging in the liver was 62.1% (126/203). The reasons for failure were a too large B
conclusionsAPT imaging could be an imaging biomarker for the differentiation of FLLs. However, further technical improvement is required before APT imaging can be clinically applied to liver MRI. KEY POINTS: • Liver APT imaging was technically feasible, but with a relatively low success rate (62.1%). • Liver metastases showed higher APT values than hepatocellular carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.